LNTH | tickerfilter.com

Fundamental analysis

65%

Profitability 66%

Dept financing 50%

Liquidity 23%

Performance 78%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

0.56%

1 Month

5.83%

3 Months

11.68%

6 Months

-7.57%

1 Year

51.31%

2 Year

19.10%

Key data

Stock price

$101.77

P/E Ratio

19.91

DAY RANGE

$99.75 - $103.81

EPS

$4.52

52 WEEK RANGE

$65.89 - $126.89

52 WEEK CHANGE

$51.31

MARKET CAP

6.220 B

YIELD

N/A

SHARES OUTSTANDING

69.431 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-01-2025

BETA

0.46

PUBLIC FLOAT

AVERAGE 10 VOLUME

$630,158

AVERAGE 30 VOLUME

$825,449

Company detail

CEO: Mary A. Heino
Region: US
Website: lantheus.com
Employees: 700
IPO year: 2015

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/In Vitro, In Vivo Diagnostic Substances
Sector: Manufacturing

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates disease burden of prostate cancer by quantifying the hotspots on bone scans.

LNTH - Lantheus Holdings, Inc.